Effect of Multifunctional Nutrition Tube on Cerebral Small Vessel Disease Patients

Launched by ZENG CHANGHAO · Feb 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a new feeding method called Intermittent Oro-esophageal Tube Feeding (IOE) for patients with Cerebral Small Vessel Diseases (CSVD) who have difficulty swallowing (dysphagia). The trial compares the IOE method to the more commonly used Nasogastric Tube (NGT) feeding. Researchers want to see if IOE can lead to better improvements in swallowing, nutrition, daily activities, quality of life, and reduce the risk of pneumonia and other complications.

To participate in this study, you must be between 40 and 70 years old, have a confirmed diagnosis of CSVD using an MRI, and have difficulty swallowing that has been assessed through specific tests. You should also be able to cooperate with the study procedures and have no significant history of stroke or other serious health issues. If you join the study, you can expect to receive comprehensive rehabilitation therapy along with the feeding method being tested. This trial is currently recruiting participants, so if you or a family member think you might qualify, it could be a great opportunity to help improve treatment options for those with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of CSVD, confirmed by MRI;
• • Must be able to cooperate with treatment and questionnaire investigation, (Generally with a Mini-Mental State Examination (MMSE) score ≥ 24) ;
• • Clinical diagnosis of dysphagia through the Functional Oral Intake Scale (FOIS) and Video Fluoroscopic Swallowing Study (VFSS);
• • Age between 40 and 70 years;
• • Enteral nutrition support was required and feasible.
• • No history of prior stroke.
• Exclusion Criteria:
• • Dysphagia related to other cerebrovascular diseases or caused by neurodegenerative diseases;
• • Complicated with severe liver and kidney failure, tumors, or hematological disorders;
• • Simultaneously need to undergo other therapy that might affect the outcomes of this study;
• • Pregnant or nursing females.